Epidemiology, XXXX , and Outcomes of @entity5131 in Adults: An Observational Cohort Study.

@entity5131 @entity1 @entity55 @entity683 @entity325 @entity1729 @entity2834
Advanced technologies using polymerase-chain reaction have allowed for @entity1729 including @entity55 . @entity325 have been described for several respiratory viruses, especially with @entity683 . Outcomes of @entity5131 , including cases with @entity325 , have not been well described.This was observational cohort study conducted to describe hospitalized @entity1 with @entity5131 including @entity325 , clinical outcomes, and predictors of mortality. @entity1 admitted from March 2013 to November 2014 with a positive respiratory virus panel (RVP) and radiographic findings of @entity55 within 48h of the index RVP were included. @entity1729 ( @entity1729 ) was defined as any organism identification from a respiratory specimen within 3 days of the index RVP. Predictors of in-hospital mortality on univariate analysis were evaluated in a multivariate model.Of 284 @entity1 with @entity5131 , a majority (51.8%) were immunocompromised. A total of 84 @entity1 (29.6%) were found to have a @entity1729 with 48 (57.6%) having a bacterial @entity1729 . Viral @entity1729 with HSV, @entity2834 , or both occurred in 28 @entity1 (33.3%). Fungal (16.7%) and other CRIs (7.1%) were less common. Many @entity1 required mechanical ventilation (54%) and vasopressor support (36%). Overall in-hospital mortality was high (23.2%) and readmissions were common with several @entity1 re-hospitalized within 30 (21.1%) and 90 days (36.7%) of discharge. Predictors of in-hospital mortality on multivariate regression included severity of illness factors, stem-cell transplant, and identification of multiple respiratory viruses. In conclusion, hospital mortality is high among adult @entity1 with @entity5131 and @entity1 with multiple respiratory viruses identified may be at a higher risk.
